文献速递艾滋病与性传播感染

高心血管风险HIV感染者从增效PI换用多替拉韦可降低可溶性CD14和脂联素

Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

NEAT022试验纳入415例高心血管风险HIV感染者,313例有配对样本,评估换用多替拉韦48周后生物标志物变化。换用多替拉韦者sCD14(-11%,P<0.001)和脂联素(-11%,P<0.001)显著下降,hsCRP和oxLDL呈下降趋势,校正基线变量后关联仍显著。

要点

  • 高心血管风险HIV感染者换用多替拉韦48周后sCD14和脂联素均下降11%。
  • sCD14下降可能有益,脂联素下降可能反映体重增加相关的胰岛素敏感性降低。
  • 换用多替拉韦对hsCRP和oxLDL的影响呈下降趋势但未达统计学显著。

核心结论

  • 高心血管风险HIV感染者从增效蛋白酶抑制剂换用多替拉韦48周后sCD14和脂联素显著降低。

研究设计与样本

  • NEAT022试验的48周生物标志物分析,415例随机,313例(75.4%)有配对样本。

主要发现

  • 换用多替拉韦者sCD14下降11%(P<0.001),脂联素下降11%(P<0.001)。
  • hsCRP下降13%(P=0.069)和oxLDL下降13%(P=0.084)呈下降趋势。
  • 校正基线变量后,换用多替拉韦仍与sCD14和脂联素降低显著相关。
  • sCD14变化与CD4计数变化呈负相关(P=0.05),脂联素变化与BMI变化呈负相关(P<0.001)。

临床怎么用

  • 对于高心血管风险的HIV感染者,从增效蛋白酶抑制剂换用多替拉韦可能通过降低sCD14带来获益。
  • 换用多替拉韦后脂联素下降可能提示体重增加和胰岛素敏感性降低,需关注代谢变化。

局限性

  • 仅75.4%的随机受试者有配对样本,可能存在选择偏倚。
  • 部分生物标志物变化仅为趋势,未达统计学显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Switching from boosted PIs to dolutegravir in people living with HIV (PLWH) with high cardiovascular risk improved plasma lipids at 48 weeks in the NEAT022 trial. Whether this strategy may have an impact on cardiovascular biomarkers is unknown. METHODS: We assessed 48 week changes in biomarkers associated with inflammation, endothelial dysfunction, monocyte immune activation, oxidation, insulin resistance, hypercoagulability, heart failure, myocardial injury, and glomerular and tubular kidney injury. RESULTS: Of 415 PLWH randomized in the NEAT022 study, 313 (75.4%) remained on allocated therapy and had paired samples available. Soluble CD14 (-11%, P < 0.001) and adiponectin (-11%, P < 0.001) significantly declined and high-sensitive C-reactive protein (-13%, P = 0.069) and oxidized LDL (-13%, P = 0.084) tended to decrease with dolutegravir. Switching to dolutegravir remained significantly associated with soluble CD14 and adiponectin reductions after adjustment for baseline variables. There were inverse correlations between soluble CD14 and CD4 count changes (P = 0.05), and between adiponectin and BMI changes (P < 0.001). CONCLUSIONS: Switching from boosted PIs to dolutegravir in PLWH with high cardiovascular risk led to soluble CD14 and adiponectin reductions at 48 weeks. While decreasing soluble CD14 may entail favourable health effects in PLWH, adiponectin reduction may reflect less insulin sensitivity associated with weight gain.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. González-Cordón A, Assoumou L, Moyle G, et al. Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV. J Antimicrob Chemother. 2021. PMID: 34120186. doi:10.1093/jac/dkab158

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。